Compare DigitalOcean Holdings Inc (DOCN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs TG Therapeutics Inc — how do they compare? DigitalOcean Holdings Inc trades at $134.22 (market cap $14.21B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: DigitalOcean Holdings Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| DOCN | TGTX | |
|---|---|---|
Market Cap | $14.21B | $7.64B |
Sector | Technology | Health |
52-Week High | $181.29 | $59.06 |
52-Week Low | $29.99 | $26.94 |
Enterprise Value | $14.97B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean (DOCN) trades at $133.47, up 2.88% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with 29% revenue growth driven by AI-native cloud demand. Profitability remains robust with a 23.27% net income margin, though valuation ratios like P/E of 54.94 are elevated. Recent news highlights AI infrastructure growth and a CEO focus on profitable expansion.
Outlook is positive with a consensus price target of $173.71 implying 30% upside, supported by accelerating revenue and AI tailwinds. Risks include high debt levels, competitive cloud market pressures, and reliance on sustained AI demand. The stock offers growth exposure but requires monitoring of execution and valuation sustainability.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
